ASPI targets $300–$700M EBITDA by 2031 via global expansion

ASPI says it is scaling globally and targeting $300–$700 million EBITDA by 2031 through expansion in radiopharmaceuticals, isotope enrichment, helium/LNG, and electronic gases, supported by proprietary technologies and disciplined capital allocation.